News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 12:45:51 2024-04-16 pm EDT			5-day change	1st Jan Change
894.8 ^USD	-0.42%		-5.20%	+1.88%

01:59am	Regeneron to defend against DOJ complaint on drug-price manipulation	RE
01:24am	Regeneron to defend US Justice Department's complaint on drug-pricing manipulation	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron to defend against DOJ complaint on drug-price manipulation	07:59pm	RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation	07:24pm	RE
Regeneron Pharmaceuticals : Statement on Department of Justice Filing Related to EYLEA® (aflibercept) Injection 2 mg	07:07pm	PU
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	Apr. 15	MT
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	Apr. 10	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	Apr. 10	DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting	Apr. 10	MT
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET	Apr. 10	DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting	Apr. 10	MT
US Justice department files complaint against Regeneron, alleges fraudulent drug pricing	Apr. 10	RE
US accuses Regeneron of fraudulent price reporting for eye drug	Apr. 10	RE
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating	Apr. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters